See more : Sundiro Holding Co., Ltd. (000571.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Vaccinex, Inc. (VCNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vaccinex, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nippon Sanso Holdings Corporation (TYNPF) Income Statement Analysis – Financial Results
- Ensurge, Inc. (ESGI) Income Statement Analysis – Financial Results
- Fintech Acquisition Corp. IV (FTIVU) Income Statement Analysis – Financial Results
- Greenlane Renewables Inc. (GRNWF) Income Statement Analysis – Financial Results
- Time Watch Investments Limited (2033.HK) Income Statement Analysis – Financial Results
Vaccinex, Inc. (VCNX)
About Vaccinex, Inc.
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 570.00K | 100.00K | 900.00K | 50.00K | 523.00K | 724.00K | 90.00K | 316.00K |
| Cost of Revenue | 0.00 | 207.00K | 169.00K | 2.00K | 199.00K | 1.03M | 160.00K | 115.00K |
| Gross Profit | 570.00K | -107.00K | 731.00K | 48.00K | 324.00K | -309.00K | -70.00K | 201.00K |
| Gross Profit Ratio | 100.00% | -107.00% | 81.22% | 96.00% | 61.95% | -42.68% | -77.78% | 63.61% |
| Research & Development | 16.57M | 13.98M | 17.16M | 21.55M | 25.67M | 22.35M | 16.55M | 16.03M |
| General & Administrative | 6.88M | 6.20M | 6.23M | 7.41M | 6.67M | 4.62M | 4.48M | 4.43M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.88M | 6.20M | 6.23M | 7.41M | 6.67M | 4.62M | 4.48M | 4.43M |
| Other Expenses | 0.00 | -175.00K | 43.00K | -575.00K | 152.00K | 165.00K | -40.00K | -4.00K |
| Operating Expenses | 23.46M | 20.01M | 23.39M | 28.38M | 32.34M | 26.97M | 21.03M | 20.46M |
| Cost & Expenses | 23.46M | 20.01M | 23.39M | 28.38M | 32.54M | 28.01M | 21.19M | 20.58M |
| Interest Income | 0.00 | 2.00K | 809.00K | 489.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.00K | 2.00K | 809.00K | 489.00K | 0.00 | 392.00K | 1.36M | 2.99M |
| Depreciation & Amortization | 119.00K | 207.00K | 169.00K | 307.00K | 249.00K | 223.00K | 206.00K | 178.00K |
| EBITDA | -19.75M | -19.61M | -21.40M | -28.06M | -31.61M | -28.90M | -17.20M | -10.78M |
| EBITDA Ratio | -3,464.56% | -19,606.00% | -2,475.33% | -56,110.00% | -6,044.74% | -3,714.50% | -23,264.44% | -6,356.01% |
| Operating Income | -22.89M | -19.91M | -22.49M | -28.33M | -32.02M | -27.28M | -21.10M | -20.26M |
| Operating Income Ratio | -4,014.91% | -19,906.00% | -2,498.89% | -56,662.00% | -6,121.41% | -3,768.09% | -23,448.89% | -6,411.08% |
| Total Other Income/Expenses | 2.63M | 91.00K | 110.00K | -520.00K | 152.00K | -2.24M | 2.35M | 6.32M |
| Income Before Tax | -20.25M | -19.82M | -22.38M | -28.85M | -31.86M | -29.52M | -18.76M | -13.94M |
| Income Before Tax Ratio | -3,552.81% | -19,815.00% | -2,486.67% | -57,702.00% | -6,092.35% | -4,077.07% | -20,843.33% | -4,412.34% |
| Income Tax Expense | 0.00 | -93.00K | 852.00K | 458.00K | 152.00K | -1.85M | 1.28M | 2.99M |
| Net Income | -20.25M | -19.72M | -23.23M | -29.31M | -32.02M | -29.52M | -18.72M | -13.94M |
| Net Income Ratio | -3,552.81% | -19,722.00% | -2,581.33% | -58,618.00% | -6,121.41% | -4,077.07% | -20,802.22% | -4,412.34% |
| EPS | -43.68 | -97.59 | -170.04 | -327.62 | -521.95 | -1.19K | -689.86 | -526.85 |
| EPS Diluted | -43.68 | -97.59 | -169.11 | -327.62 | -521.95 | -1.19K | -689.86 | -526.85 |
| Weighted Avg Shares Out | 463.65K | 202.08K | 136.63K | 89.46K | 61.34K | 24.87K | 27.14K | 26.47K |
| Weighted Avg Shares Out (Dil) | 463.65K | 202.08K | 137.38K | 89.46K | 61.34K | 24.87K | 27.14K | 26.47K |
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Actively Exploring Partnership for Alzheimer's Development Supplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition...
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Partnerships will employ Vaccinex's ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting
Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer. Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of...
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain
Company describes new biomarker and cognitive treatment effects that support continued development of pepinemab in Mild Cognitive Impairment and Mild Dementia due to Alzheimer's disease Company describes new biomarker and cognitive treatment effects that support continued development of pepinemab in...
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, announced today...
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership
ROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease.
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease
Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation,believed to be key drivers of neurodegeneration.
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
Last patient last visit in SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer's Disease in early June 2024. $8.2 million of new financing in Q1.
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
Expect Topline Data for Randomized SIGNAL-AD Study of Pepinemab for Alzheimer's Disease in Q3 2024. $17.9 million of new financing in Q4 2023 and Q1 2024.
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease and cancer through the inhibition of SEMA4D, today announced that it has...
Source: https://incomestatements.info
Category: Stock Reports